Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.

Molecular cancer - 23 Feb 2017

Agudo-López Alba, Prieto-García Elena, Alemán José, Pérez Carlos, Díaz-García C Vanesa, Parrilla-Rubio Lucía, Cabrera Silvia, Navarro-Ranninger Carmen, Cortés-Funes Hernán, López-Martín José A, Agulló-Ortuño M Teresa

Abstract excerpt

BACKGROUND: Cisplatin is a potent antitumor agent. However, toxicity and primary and secondary resistance are major limitations of cisplatin-based chemotherapy, leading to therapeutic failure. We have previously reported that mono-sulfonamide platinum complexes have good antitumor activity against different tumoral cell lines and with a different and better cytotoxic profile than cisplatin. Besides,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Cyclin-Dependent Kinase Inhibitor p27

Share to Drug Synergism

Share to Melanoma

Share to Organoplatinum Compounds

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 28231799
DOI: 10.1186/s12943-017-0618-7
PMCID: PMC5324334

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.PMID 28231799Read ↗

Metal-based anticancer drugs: From a past anchored in platinum chemistry to a post-genomic future of diverse chemistry and biologySemantic proximity Read ↗

Can Cisplatin Therapy Be Improved? Pathways That Can Be TargetedSemantic proximity Read ↗

Novel Approaches Towards Development of Non-Classical Platinum-Based Antineoplastic Agents: Design of Platinum Complexes Characterized by an Alternative DNA-Binding Pattern and/or Tumor-Targeted CytotoxicitySemantic proximity Read ↗

Platinum Complexes as Anticancer AgentsSemantic proximity Read ↗

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapySemantic proximity Read ↗

Triple action Pt( iv ) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistanceSemantic proximity Read ↗

Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic PathwaysSemantic proximity Read ↗

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of ResistanceSemantic proximity Read ↗

Fresh Platinum Complexes with Promising Antitumor ActivitySemantic proximity Read ↗

Metallodrugs: an approach against invasion and metastasis in cancer treatmentSemantic proximity Read ↗

Inhibition mechanism of naphthylphenylamine derivatives acting on the CDC25B dual phosphatase and analysis of the molecular processes involved in the high cytotoxicity exerted by one selected derivative in melanoma cells.Semantic proximity Read ↗

Biomolecular Targets for Platinum Antitumor DrugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.